Clinical medicine profile
L-Ornithine-L-Aspartate
Insulin (antidiabetic hormone)
- Route
- SC / IV (soluble in critical care)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypoglycaemia.
- Hypersensitivity to specific formulation.
Precautions
- HIGH-ALERT medication.
- Dose double-checks.
- Educate hypo recognition/treatment.
- Adjust for renal failure (reduced clearance), illness, steroids, exercise.
- Never share pens.
- Rotate sites.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dose: 1-2 sachets or tablets TID, dissolved in liquid with or after a meal.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Reduced insulin clearance — lower doses often needed in advanced CKD.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Impaired gluconeogenesis increases hypo risk.
Use, effects & interactions
Indications
- High ammonia levels
- severe liver impairment
- end-stage cirrhosis Clinical selection for L-Ornithine-L-Aspartate should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Insulin (antidiabetic hormone).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Hypoglycaemia, weight gain, injection-site reactions, lipodystrophy.
- Rare: severe allergy, hypokalaemia (shift).
Drug interactions
Open multi-drug checker ↗- ISMP high-alert.
- Write units in full.
- Confirm concentration (U-100 vs U-200/U-300/U-500).
- Sick-day rules and ketone advice for type 1.
- Structured education improves outcomes.
Mechanism & disposition
Insulin binds insulin receptors, promoting GLUT4-mediated glucose uptake in muscle/adipose tissue, stimulating glycogenesis, inhibiting glycogenolysis/gluconeogenesis and lipolysis — lowers blood glucose.
Read complete mechanism
Insulin binds insulin receptors, promoting GLUT4-mediated glucose uptake in muscle/adipose tissue, stimulating glycogenesis, inhibiting glycogenolysis/gluconeogenesis and lipolysis — lowers blood glucose.
Minutes–hours (formulation-dependent)
Hours–>40 h (basal analogues)
SC / IV (soluble in critical care)
varies by site, temperature, lipohypertrophy. Analogues engineered for prandial vs basal profiles. IV soluble insulin used in DKA/HHS protocols.
Pregnancy, lactation & diet
Insulin is preferred pharmacological therapy for diabetes in pregnancy when needed.
Compatible; may need dose adjustment postpartum.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.